Health · BATS · USD · Data as of 2026-07-30
AUM
$1.73B
Expense ratio
0.75%
Yield
0.00%
YTD return
+45.43%
Last price
$37.47
Thematic Sector · Coverage 100% · medium
Today
43.7
Outlook
46.6
Block A (composite-derived)
45.6
Block C (market behavior)
40.6
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
45.6
Coverage 100% · high
Liquidity
84.2
Expenses
45.0
Performance
41.4
Volatility
5.9
Dividend
3.6
Concentration
25.0
Smart Money
63.3
Activist
100.0
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund from ARK ETF Trust in the Mixed asset class. Launched in 2014. Assets under management: 1,235,872,256.
Bullish Whales composite rating: 46 out of 100. Evidence coverage 100% across 8 of 8 axes. Strongest axes: activist exposure, liquidity, smart-money flow.
Annualized one-year realized volatility 41%, classified high. Weakest axes: dividend, volatility.
Top-10 weight 1%, diversified, led by TEM.
etf_composite_score_current · activist_score, composite_score, confidence, coverage_pct, dividend_score, liquidity_score, smart_money_score, volatility_scoreetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yARK Genomic Revolution ETF is an actively managed exchange-traded fund focused on companies tied to the genomics revolution. ARK Genomic Revolution ETF seeks exposure to businesses involved in areas such as DNA sequencing, gene editing, CRISPR-based tools, molecular diagnostics, bioinformatics, and precision therapeutics. The portfolio is designed to capture companies that develop, enable, or benefit from scientific advances in genomic healthcare and related life sciences. Its holdings typically span healthcare and adjacent innovation-driven sectors, with an emphasis on firms offering products and services used in research, clinical testing, and next-generation medical applications. As a thematic equity ETF, ARK Genomic Revolution ETF serves as a concentrated vehicle for investors looking to access a specialized segment of the healthcare and biotechnology market through a single fund.
30-day change
$422.77M
90-day change
—
Current AUM: $1,729,676,032. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for ARKG are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.